Going PRO: FDA Suggests Best Practices For Choosing, Changing Patient-Reported Outcome Tools
Patient-Reported Outcome (PRO) instruments are the focus of a 26 January final guidance from the US agency. Sponsors can lean on the guidance when selecting, developing or modifying tools for patient data collection.
You may also be interested in...
The US agency has qualified the FACE-Q | Aesthetics patient-reported outcome instrument through its MDDT program.
Artificial intelligence, machine learning, and virtual and augmented reality are among the themes under consideration for future MDDTs from the US agency.
In this FINAL EPISODE of Speaking Of Medtech: The US FDA got something it desperately wanted in its latest user-fee package with industry: a Total Product Lifecycle Advisory Program pilot, or TAP. The agency says TAP will allow for earlier and more frequent engagement with developers – but is it needed?